CASP9

Across TCGA pan-cancer cohorts, CASP9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CASP9 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CASP9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASP9 expression acts as an unfavorable survival marker.

SCLC, BRCA, and TGCT are the cancer types where CASP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
BRCA	OS	Median	III,IV	0.165	0.833	<.001	20	view →
TGCT	DFS	Median	II,III,IV	0.088	0.917	.010	6	view →
BLCA	OS	Median	IV	0.182	0.596	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CASP9–SCLC (OS)

Open the SCLC breakdown →